

June 2nd, 2009

NRC License # 48-32697-01

Material Licensing Branch U.S. Nuclear Regulatory Commission, Region III 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352 ATTN: Colleen Casey

Northern Shared Medical Services would like to add two additional authorized users to our radioactive materials license. The authorized users are as follows:

**Authorized Users:** 

Peter D. Arfken, M.D. Theodore P. Labus, M.D.

NRC Lic# 13-16286-01 NRC Lic# 13-16286-01

Thank you for your kind attention. If any questions should arise, please feel free to contact me 608-839-9956.

Sincerely,

Lisa Arington, CEO

**Northern Shared Medical Services** 

NKL FURM 3/4	NRC	FORM	374
--------------	-----	------	-----

## U.S. NUCLEAR REGULATORY COMMISSION

PAGE \_\_ 1 OF \_\_4 PAGES Amendment No. 34

## **MATERIALS LICENSE**

Purruant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Fed and Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations here tofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, sou ce, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to

Licensee	In accordance with letter dated March 12, 2009,
liverview Hospital	3. License number 13-16286-01 is amended in
	its entirety to read as follows:
95 Westfield Road	4. Expiration date October 31, 2010
P.O. Box 220 Noblesville, IN 46060	5. Docket No. 030-10729 Reference No.
Syproduct, source, and/or special 7. Chemical and/or proclear material	A
A. Any byproduct material A. Any permitted by 10 CFR 35.100	A. As needed
Any byproduct material B. Any permitted by 10 CFR 35.200	B. As needed
Any byproduct material C. Any permitted by 10 CFR 35.300	C. As needed (not to exceed one curie of I-131)
Any byproduct material     permitted by 10 CFR 3 15 1.	ed Kits D. As needed
Authorized Use:	
A. Any uptake, dilution and excretion study permit	ited by 10CFR 35.100.
B. Any imaging and localization study permitted t	
C. Any diagnostic study or therapy procedure per	mitted by 10CFR 35.300.
D. <u>In vitro</u> studies.	

- Indiana.
- The Radiation Safety Officer for this license is Phillip R. Partlan, R.T.

	N.C. MICH SAT DECIMATED COMMISSION	1					
NF 3 FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	4	PAGES
		13-16286-01					
MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-10729					-
		Amendment No. 34					

- 12 Licensed material is only authorized for use by, or under the supervisionof:
  - A. Individuals permitted to work as an authorized user in accordance with 10CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

	Authorized Users	Material and Use
	Anthony J. Cossell, M.D.	10 CFR 35.100, 35.200, and 31.11.
	William E. McGraw, M.D.	10 CFR 35.100 and 35.200.
	John Mark Michael, M.D.	10 CFR 35.100, 35.200 and 35.300.
	Richard L. Hallett, M.D.	10 CFR 35.100, 35.200 and 35.300.
-	Peter D. Arfken, M.D.	10 CFR 35.100, 35.200 and 35.300.
	John A. Morton, M.D.	10 CFR 35,100, 35,200, 35,300 and 31,11.
	Margaret Brengle, M.D.	10 CFR 35.100 and 35.200.
	Jeffrey I. Reider, M.D.	10 CFR 35 100 and 35 200.
	Homer F. Beltz, M.D.	10:CFR 35.100 and 35.200.
	Michael S. Skulski, M.D.	10 CFR 35 100 and 35 200.
	Richard T. Beeler, M.D.	10 CFR 35 100, 35.200 and 35.300.
	Steven A. Fritsch, M.D.	10 CFR 35 100 and 35 200.
	Frank J. Pistoia, M.D.	10 CFR 35.100 and 35.200.
	Michael A. Kuharik, M.D.	10 CFR 35,100 and 35,200
	Janalyn P. Ferguson, M.D.	10 CFR 35.100 and 35.200.
	Jane S. Mitchell, M.D.	10 CFR 35.100 and 35.200.
	Jack J. Moss, M.D.	10 CFR 35.100 and 35.200.
	Lori J. Wells, M.D.	10 CFR 35,100 and 35,200.
	Eric D. Elliott, M.D.	10 CFR 35.100 and 35.200.
	Charles A. Lerner, M.D.	10 CFR 35.100 and 35.200.

NF C FORM 374A U.S. NUCLEAR RI	EGULATORY COMMISSION	1	PAGE	^			
		License Number 13-16286-01	PAGE	3	of	4	PAGES
	MATERIALS LICENSE SUPPLEMENTARY SHEET						
		Amendment No. 34					
Thomas Hagman, M.D.	10 CFR 35.100, 35	5.200 and 35.300.	-				
Brian J. Weigel, M.D.	10 CFR 35.100, 35	5.200 and 35.300.					
Jack M. Drew, M.D.	10 CFR 35 400, 35	5.200 and 35.300.					
David R. Gulliver, M.D.	10 CFR 35.100, 35	5.200 and 35:300,					
J. Michael Phelps, Jr., M.D.	10 CFR 35.100, 35 iodide-131 in quant	5.200, and 35.300 (Oral titles less than or equal	admir I to 33	nistra milli	ation curie	ofs ∋s).	odium
Timothy L. Davis, M.D.	10 CFR 35.100, 35 iodide-131 in quant	i.200, and 35.300 (Oral tities less than or equal	admir I to 33	nistra milli	ation curie	ofs ∋s).	odium
Vincent P. Mathews, M.D.	10 CFR 35.100 and	d 35.200.					
→Theodore P. Labus, M.D.	40 CFR 35.100, 35	.200 and 35,300.					
Cristina N. Shinaver, M.D.	10 CFR 35.100, 35	.200,and 35.300.					
Edward R. Bartley, M.D.	10 CFR*35.100-and	i 35 200.					
Caryn Cockerill Anderson, M.D.	10 <b>`</b> CFR 35.100 and	1 35 200.					
Warren Kent Hansen∖M:D.	10(CFR 35.100, 35 sodium lodide-131 i millicuries).	.200, and 35/300 (Oral in guantities/less than o	admir or equa	nistra al to	ation 33	of	
Carlo Robert Lazzaro, M.D.	10 CFR 35 100, 35 sodium jodide-131 i		admir or equa	nistra al to	ation 33	of	
Charles C. Mulry, M.D.	10 CFR 35.100, 35. sodium iodidel 31 i millicuries).	200, and 35,300 (Oral n quantities less than o	admin or equa	istra alto	tion 33	of	
Eric E. Beltz, M.D.	10 CFR 35 100, 35. administration of so to 33 millicuries)	200, and 35.300 (Limit dium iodide-131 in qua	ed to t ntities	he o less	rai thar	n or	equal
Laura Dugan, M.D.	10 CFR 35.100 and	35.200					
Jonathan Kahn, M.D.	10 CFR 35.100, 35.	200 and 35.300					

in addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

NFC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	P	AGE	4	of	4	PAGES
	MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-16286-01					
		Docket or Reference Number 030-10729					
		Amendment No. 34	SIII				

- 14 The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 15 Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition apples only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 3526. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements. representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - Application dated September 21, 2000 (except Item 12.1); and
  - Facsimiles dated November 20, 2000, July 26, 2007, July 7, 2008, and July 14, 2008, and;
  - C. Letters dated August 2, 2001, August 23, 2001, November 6, 2001, January 14, 2002 (with enclosed close-out survey of old Nuclear Cardiology room), March 26, 2002 (with enclosed close-out survey of old nuclear medicine department), March 28, 2002; June 9, 2006 and June 19, 2007; and
  - Facsimiles letter dated September 7, 2006 December 8, 2008.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

APR 2 3 2009

James R. Mullauer M.H.S.

Materials Licensing Branch

Région III

916/9//

Dare



This letter is to authorize Shared Medical Services to use radioactive materials for PET/CT imaging at: <u>Riverview Hospital 395 Westfield Rd</u>, <u>Noblesville IN 46060</u>, Institution & address

We understand that radioactive materials intended for PET/CT imaging studies on the coach will be received and utilized at the coach under the radioactive materials license issued to Shared Medical Services.

> Larry Christman CFO / COO Name and Title

> > Signature

Date

This envelope is for use with the following services: UPS Next Day Air®

1 OF 1

UPS Next Day Air® UPS Worldwide Express™ UPS 2nd Day Air®

Do not use this envelope for:

**UPS Worldwide Expedited™** 


**UPS** Ground


**UPS Standard** 

UPS 3 Day Select™

Apply shipping documents on this side.

## Call 1-800-PICK-UPS® (1-800-742-5877) or visit UPS.com®.







UPS 2ND DAY AIR
TRACKING #: 1Z 524 1E8 02 4425 7080



BILLING: P/P

Billing ID: XFL-2 Description:

MS 11.0.15

LP2844 90 0A 04/2009



Cottain from the Second Content to 4 (the Variana Contention) while the Contention of Co-Content to the instructions Content for the Co-Content to the Contention Content to the Content t

100% Recycled fiber 80% Post-Consumer

International Shipping Notice — Carriage horseneder may be subject to the rules relating to Hability and other terms and/or conditions established by the Convention of the Unification of Certain Rules Relating to International Carriage by Air (the "Warsaw Convention") and/or the Convention on the Contract for the International Carriage of Goods by Road (the "CMR Convention"). These commodities, technology or software were exported from the U.S. in accordance with the Export Administration Regulations. Diversion contrary to U.S. law prohibited.